These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24369279)

  • 21. [Role of estrogen and selective estrogen receptor modulators in anti-aging].
    Ohta H
    Clin Calcium; 2008 Jul; 18(7):986-94. PubMed ID: 18591752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Estrogens and selective estrogen receptor modulators in the treatment of osteoporosis].
    Ribot C; Tremollieres F; Pouilles JM
    Ann Med Interne (Paris); 2000 Oct; 151(6):490-6. PubMed ID: 11104929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis.
    Nelson ER; Wardell SE; McDonnell DP
    Bone; 2013 Mar; 53(1):42-50. PubMed ID: 23168292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of SERMs on bone health. SERM and metabolic markers of bone].
    Takami M; Shimada H
    Clin Calcium; 2010 Mar; 20(3):365-71. PubMed ID: 20190366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy].
    Burckhardt P
    Schweiz Med Wochenschr; 1999 Dec; 129(49):1926-30. PubMed ID: 10635085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SERMs: progress and future perspectives.
    Pickar JH; MacNeil T; Ohleth K
    Maturitas; 2010 Oct; 67(2):129-38. PubMed ID: 20580502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Oral osteoporosis: a review and its dental implications].
    Inagaki K; Kurosu Y; Sakano M; Yamamoto G; Kikuchi T; Noguchi T; Yano H; Izawa H; Hachiya Y
    Clin Calcium; 2007 Feb; 17(2):157-63. PubMed ID: 17272871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH; Mirkin S
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone.
    Thiebaud D
    J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S124-5. PubMed ID: 21213508
    [No Abstract]   [Full Text] [Related]  

  • 30. [Osteoporosis].
    Miyamoto T; Toyama Y
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():623-7. PubMed ID: 23513914
    [No Abstract]   [Full Text] [Related]  

  • 31. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
    Gorai I;
    Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current topics in drug therapy aiming at bone resorption].
    Yasui T; Tanaka S
    Clin Calcium; 2006 Sep; 16(9):1475-79. PubMed ID: 16951471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A-TOP research group/JOINT-02].
    Kuroda T; Ohta H; Shiraki M; Miyakawa N; Hosoi T; Nakamura T; Fukunaga M; Orimo H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():271-4. PubMed ID: 18161118
    [No Abstract]   [Full Text] [Related]  

  • 36. HT and SERMs in the long-term management of osteoporosis.
    Tuppurainen M
    Minerva Ginecol; 2012 Jun; 64(3):195-205. PubMed ID: 22635015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy for treatment of osteoporosis: A review.
    Pinkerton JV; Dalkin AC
    Am J Obstet Gynecol; 2007 Dec; 197(6):559-65. PubMed ID: 18060937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duration of treatment for osteoporosis.
    Idolazzi L; Fassio A; Gatti D; Tamanini S; Viapiana O; Rossini M; Adami S
    Reumatismo; 2013 Mar; 65(1):22-35. PubMed ID: 23550257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
    Gennari L
    Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.